Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14148803 | 0.86 | EGFR (0.40) | EGFRKDM4EMEN1POLBGAA | |
| SCHEMBL4731185 | 0.79 | EGFR (0.45) | EGFRKDM4EMEN1POLBGAA | |
| SCHEMBL20203376 | 0.77 | ALDH1A1 (0.55) | KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL17071910 | 0.77 | SMN1; SMN2 (0.45) | GAAMAPTRAB9AALDH1A1 | |
| SCHEMBL14148734 | 0.75 | IAPP (0.48) | EGFR | |
| SCHEMBL14148738 | 0.75 | EGFR (0.69) | EGFRALDH1A1 | |
| SCHEMBL18556990 | 0.74 | EGFR (0.31) | EGFR | |
| SCHEMBL14148802 | 0.74 | TTR (0.46) | EGFR | |
| SCHEMBL26522130 | 0.73 | CYP1A1 (0.43) | MEN1POLBMAPTRAB9AKMT2A | |
| SCHEMBL14148735 | 0.70 | EGFR (0.43) | EGFRKDM4EGAAMAPTSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580553-B2 | Thermally-activated self-immolative materials | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150368403-A1 | THERMALLY-ACTIVATED SELF-IMMOLATIVE MATERIALS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368403-A1 | THERMALLY-ACTIVATED SELF-IMMOLATIVE MATERIALS | PARG, PAICS, LRBA | EGFR 3270/4885KDM4E 4706/4885MEN1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.